Yazdi H, et al. - Whether treatment with intravenous tranexamic acid (TXA) would lead to a reduction in periprosthetic joint infection (PJI) following total joint arthroplasty (TJA), was investigated in this study, utilizing an institutional database. Researchers selected 6,340 patients receiving primary TJA from January 1, 2013, to June 31, 2017, and were observed over a minimum duration of 1 year. There were two groups of patients: 3,683 (58.1%) who received TXA and 2,657(41.9%) who did not receive TXA. A link of TXA with reduced PJI following primary TJA was revealed in multivariate regression analysis, after adjusting for all confounding variables. Experts viewed TXA as a helpful option to decrease the rate of PJI following primary TJA. A likely interconnection of this protective influence with a decrease in blood loss, lower requirement for allogeneic blood transfusion and issues associated with immunomodulation related to blood transfusion was also suggested.